A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 20 Jul 2017 Planned End Date changed from 1 Apr 2020 to 23 Apr 2020.
- 10 Jan 2017 Planned End Date changed from 1 May 2020 to 1 Apr 2020.
- 10 Jan 2017 Status changed from recruiting to active, no longer recruiting.